[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Equilyse [@equilyse1](/creator/twitter/equilyse1) on x XXX followers Created: 2025-07-23 11:35:58 UTC $ISRG: Intuitive Surgical (ISRG) reported strong Q2 2025 earnings, driven by Da Vinci X adoption. Revenue jumped XX% and pro forma operating margin hit 39%. Management raised 2025 Da Vinci procedure growth guidance to 15.5%-17%. ISRG placed XXX Da Vinci X systems in Q2, bringing the installed base to XXX. Procedure growth was strong at 17%, led by benign general surgery in the U.S. and non-urology procedures internationally. SP procedures surged 88%, fueled by growth in Korea, while ION procedures grew XX% to XXXXXX. ISRG is also innovating with Force Feedback and Extended Use instrumentation, plus digital tools like Intuitive telepresence and Case Insights—an AI-enabled solution. ISRG repurchased XXXXXXX shares at an average of $XXX. They are addressing competition from third-party remanufacturers, emphasizing safety and reliability. The company also sees increased opportunities in ASCs and received FDA approval for the Vessel Sealer Curved, targeting procedures with narrow spaces.  XXX engagements  **Related Topics** [adoption](/topic/adoption) [da vinci](/topic/da-vinci) [$dgpa](/topic/$dgpa) [$isrg](/topic/$isrg) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/equilyse1/status/1947984028033777834)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Equilyse @equilyse1 on x XXX followers
Created: 2025-07-23 11:35:58 UTC
$ISRG: Intuitive Surgical (ISRG) reported strong Q2 2025 earnings, driven by Da Vinci X adoption. Revenue jumped XX% and pro forma operating margin hit 39%. Management raised 2025 Da Vinci procedure growth guidance to 15.5%-17%. ISRG placed XXX Da Vinci X systems in Q2, bringing the installed base to XXX.
Procedure growth was strong at 17%, led by benign general surgery in the U.S. and non-urology procedures internationally. SP procedures surged 88%, fueled by growth in Korea, while ION procedures grew XX% to XXXXXX. ISRG is also innovating with Force Feedback and Extended Use instrumentation, plus digital tools like Intuitive telepresence and Case Insights—an AI-enabled solution.
ISRG repurchased XXXXXXX shares at an average of $XXX. They are addressing competition from third-party remanufacturers, emphasizing safety and reliability. The company also sees increased opportunities in ASCs and received FDA approval for the Vessel Sealer Curved, targeting procedures with narrow spaces.
XXX engagements
Related Topics adoption da vinci $dgpa $isrg stocks healthcare